×
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
OTCMKTS:ESALY

Eisai (ESALY) Stock Forecast, Price & News

$42.25
+0.32 (+0.76%)
(As of 05/27/2022 12:00 AM ET)
Add
Compare
Today's Range
$41.93
$42.25
50-Day Range
$41.33
$49.46
52-Week Range
$41.18
$129.79
Volume
9,509 shs
Average Volume
25,859 shs
Market Capitalization
$12.53 billion
P/E Ratio
27.61
Dividend Yield
2.48%
Beta
0.42
30 days | 90 days | 365 days | Advanced Chart
Receive ESALY News and Ratings via Email

Sign-up to receive the latest news and ratings for Eisai and its competitors with MarketBeat's FREE daily newsletter.

Eisai logo

About Eisai

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Private households
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:ESALY
Employees
11,237
Year Founded
N/A

Sales & Book Value

Annual Sales
$6.74 billion
Cash Flow
$2.47 per share
Book Value
$23.07 per share

Profitability

Net Income
$427.17 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$12.53 billion
Optionable
Not Optionable

Company Calendar

Last Earnings
8/04/2021
Today
5/28/2022
Fiscal Year End
3/31/2023

MarketRank

Overall MarketRank

1.75 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.4Dividend Strength: 2.5Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -













Eisai (OTCMKTS:ESALY) Frequently Asked Questions

Is Eisai a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eisai in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Eisai stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ESALY, but not buy additional shares or sell existing shares.
View analyst ratings for Eisai
or view top-rated stocks.

Are investors shorting Eisai?

Eisai saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 16,600 shares, an increase of 67.7% from the March 31st total of 9,900 shares. Based on an average trading volume of 48,400 shares, the short-interest ratio is currently 0.3 days.
View Eisai's Short Interest
.

How were Eisai's earnings last quarter?

Eisai Co., Ltd. (OTCMKTS:ESALY) issued its quarterly earnings results on Wednesday, August, 4th. The company reported $1.34 earnings per share for the quarter, beating the consensus estimate of $1.09 by $0.25. The company earned $1.82 billion during the quarter. Eisai had a trailing twelve-month return on equity of 6.48% and a net margin of 6.53%.
View Eisai's earnings history
.

Is Eisai a good dividend stock?

Eisai pays an annual dividend of $1.04 per share and currently has a dividend yield of 2.48%. The dividend payout ratio of Eisai is 67.97%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Eisai will have a dividend payout ratio of 54.45% next year. This indicates that Eisai will be able to sustain or increase its dividend.

What guidance has Eisai issued on next quarter's earnings?

Eisai updated its FY 2023 earnings guidance on Friday, May, 27th. The company provided EPS guidance of $1.37-$1.37 for the period. The company issued revenue guidance of $6.03 billion-$6.03 billion.

Who are Eisai's key executives?
Eisai's management team includes the following people:
  • Mr. Haruo Naito, CEO, Representative Corp. Officer & Director (Age 75, Pay $914.71k)
  • Mr. Gary Hendler, Sr. VP & Pres of EMEA Region (Age 56, Pay $1.09M)
  • Dr. Lynn D. Kramer FAAN, M.D., VP & Group Chief Clinical Officer - Neurology Bus. Group (Age 72, Pay $930.34k)
  • Ms. Yanhui Feng, Sr. VP (Age 50, Pay $859.98k)
  • Dr. Nadeem Sarwar Ph.D., Pres
  • Mr. Ryohei Yanagi, Exec. VP & CFO (Age 60)
  • Ms. Sayoko Sasaki, Chief IR Officer Stakeholder Communications & VP (Age 54)
  • Mr. Kenta Takahashi, Exec. VP, Gen. Counsel & Intellectual Property Internal Audit (Age 63)
  • Mr. Mitsuaki Tanaka, Chief Compliance Officer, Internal Control, Chief Information Security Officer & VP (Age 60)
  • Mr. Yasushi Okada, Representative Corp. Officer, COO, Industry Affairs, China Bus. & Data Integrity (Age 64)
What is Eisai's stock symbol?

Eisai trades on the OTCMKTS under the ticker symbol "ESALY."

How do I buy shares of Eisai?

Shares of ESALY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eisai's stock price today?

One share of ESALY stock can currently be purchased for approximately $42.25.

How much money does Eisai make?

Eisai has a market capitalization of $12.53 billion and generates $6.74 billion in revenue each year. The company earns $427.17 million in net income (profit) each year or $1.529990 on an earnings per share basis.

How many employees does Eisai have?

Eisai employs 11,237 workers across the globe.

What is Eisai's official website?

The official website for Eisai is www.eisai.co.jp.

How can I contact Eisai?

Eisai's mailing address is 4-6-10 Koishikawa Bunkyo-ku, Tokyo M0, 112-8088. The company can be reached via phone at (133) 817-3700 or via fax at 813-3811-6032.

This page was last updated on 5/29/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.